

Datasheet: HCA263

Description:	HUMAN ANTI TRASTUZUMAB (DRUG/TARGET COMPLEX)
Specificity:	TRASTUZUMAB DRUG/TARGET COMPLEX
Other names:	HERCEPTIN®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD25279
Isotype:	HuCAL Fab bivalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A bivalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in *E. coli*. This Fab fragment is bivalent by dimerization of the bacterial alkaline phosphatase fusion protein. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain.

Preparation

Metal chelate affinity chromatography

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Trastuzumab

Specificity

Human anti trastuzumab drug/target complex, clone AbD25279, is a bivalent Fab antibody that specifically recognizes trastuzumab when in a complex with its target, the extracellular domain of the human epidermal growth factor receptor 2 (HER2, also known as ErbB2). It does not recognize the free drug or unbound HER2. The antibody can be used in pharmacokinetic (PK) antigen capture format assays to measure trastuzumab that has been captured via immobilized HER2. It is ideal for bioanalytical assays to measure the level of drug or biosimilar in complex with the HER2

target.

Trastuzumab (trade name Herceptin®) is a drug used in the treatment of HER2 positive breast cancer and other HER2 overexpressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.

[View a summary of all anti-trastuzumab antibodies](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=31$ nM by real time, label-free molecular interaction analysis on immobilized trastuzumab/ErbB2 complex.
ELISA	This product may be used as a detection reagent in a direct or an indirect ELISA for trastuzumab captured by immobilized human ErbB2. Protocol: PK antigen capture ELISA to measure bound drug exclusively
References	1. Harth, S. <i>et al.</i> (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. MAbs. 11 (1): 178-190.
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[MOUSE ANTI PENTA HISTIDINE TAG:HRP \(MCA5995P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[RAT ANTI DYKDDDDK TAG:HRP \(MCA4764P\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com
'M335219:181204'

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

Printed on 20 May 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)